江苏省科技期刊可视化阅读平台

导航条

江苏科技信息 ›› 2015, Vol. 32 ›› Issue (19): 72-75.doi: 10.3969/j.issn.1004-7530.2015.19.028

• 论文 • 上一篇    下一篇

VEGF在增生期血管瘤患儿用普萘洛尔治疗外周血中的表达

赵忠芳, 王蕊, 马少林   

  1. 新疆医科大学第一附属医院,新疆乌鲁木齐,830054;青岛市立医院疼痛科,山东青岛,266000
  • 出版日期:2015-07-05 发布日期:2015-07-05

The Changement of VEGF in the Serum of Proliferative Hemangioma Patients before and after the Treatment of Propranolol

Zhao Zhongfang, Wang Rui, Ma Shaolin   

  • Online:2015-07-05 Published:2015-07-05

摘要： 为研究普萘洛尔口服治疗增生期血管瘤及对血清VEGF水平的影响,文章采用酶联免疫吸附测定法(ELISA)检测患者分别服药4,8周后血清血管内皮生长因子(VEGF)水平变化及与预后的关系.服药前、服药4周和服药8周后血清血管内皮生长因子水平呈下降趋势,治疗后8周VEGF水平显著低于治疗前(P<0.05).结果证明,普萘洛尔可以通过降低患者血清VEGF水平,从而治疗增生期血管瘤.

关键词: 增生期血管瘤, 普萘洛尔, VEGF

Abstract: To study the treatment of proliferative hemangiomas by oral propranolol,and its effect to the serum VEGF levels,the paper uses ELISA assay of VEGF level in the serum of patients taking 4,8 weeks of propranolol and its relationship with the prognosis. Before treatment, the VEGF level of serum is the highest ,but after taking the drug for 4 weeks and 8 weeks,VEGF levels decreased gradually,VEGF levels were significantly lower than 8 weeks ago,before treatment(P<0.05).The paer draws the conclusions that propranolol has treatment to proliferative hemangiomas by reducing serum VEGF,levels of the patients.